Katherine Goodrich Sells Shares of Tarsus Pharmaceuticals

Katherine Goodrich, an insider at Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS), sold 2,954 shares of the company on June 15, 2026. The shares were sold at an average price of $62.08, amounting to a total transaction value of approximately $183,384. This transaction was planned in advance.

Other Institutional Activity in Tarsus Pharmaceuticals

Several institutional investors have recently adjusted their positions in Tarsus Pharmaceuticals. Deep Track Capital, LP increased its holdings by 595,966 shares, ending with 3,600,000 shares valued at about $252.54 million. In contrast, BlackRock, Inc. reduced its position by 237,945 shares, leaving it with 3,552,612 shares worth roughly $249.22 million. RTW Investments, LP added 10,705 shares, bringing its total to 3,346,025 shares valued at approximately $234.72 million. Paradigm Biocapital Advisors LP maintained its holdings at 2,562,154 shares, valued at $179.74 million. Janus Henderson Group PLC increased its stake by 310,638 shares, holding 2,240,963 shares worth about $157.22 million.

Tarsus Pharmaceuticals, Inc. Stock Down 15.3%

Shares of Tarsus Pharmaceuticals traded near $60.80. The company has a market cap of approximately $2.62 billion and a forward P/E ratio of 21.21. Its beta stands at 0.506, indicating lower volatility compared to the broader market. The stock has experienced a 52-week low of $38.51 and a high of $85.25. It has a 50-day moving average of $63.53 and a 200-day moving average of $68.22. The company maintains a strong liquidity position with a current ratio of 3.74 and a quick ratio of 3.53, alongside a debt-to-equity ratio of 25.41.

Recent Earnings

Tarsus Pharmaceuticals reported revenue of $535.08 million with a revenue growth rate of 6.9%. Despite this growth, the company posted a net margin of -9.02% and a return on equity of -13.96%, indicating ongoing profitability challenges. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.

In addition to Katherine Goodrich's transaction, several other insider trades occurred recently. On June 16, 2026, Jeffrey Farrow, the Chief Financial Officer and Chief Strategy Officer, sold 14,396 shares at $60.95 each. On the same day, William Link PhD sold 12,500 shares at an average price of $62.12 as part of a planned transaction. Earlier, on June 15, 2026, Farrow also purchased 27,881 shares without a disclosed price.

Analysts Set New Price Targets

Analysts continue to show optimism for Tarsus Pharmaceuticals. On May 4, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $88. Oppenheimer and Guggenheim both maintained 'buy' ratings in February 2026, with price targets of $105 and $90, respectively. Overall, the consensus among nine analysts is a 'strong buy,' with a target mean price of $94.11.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company based in Irvine, California. Founded in 2016, it focuses on developing and commercializing treatments for eye care. Its flagship product, XDEMVY, is an ophthalmic solution targeting demodex blepharitis. The company is also working on other therapeutic candidates, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention. Led by CEO Dr. Bobak R. Azamian, Tarsus is committed to addressing unmet medical needs in eye care and infectious disease prevention.

Bottom Line

Katherine Goodrich's recent stock sale reflects planned insider activity at Tarsus Pharmaceuticals. The company remains a focal point for investors due to its promising therapeutic pipeline and the attention it receives from analysts. While the insider transactions provide insights into management's actions, they are backward-looking and do not necessarily indicate future performance.